Nuclear Medicine

177Lu DOTATATE (I+D)

Name:
177Lu Dotatate (I+D)

Active Principle:
Lutetium (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl) acetyl]-Dphenylalanyl- L-cysteinyl-L-tyrosyl-D-tryptophanyl-L -lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic (2-7) disulfide.

Therapeutic Action:
It is a radiolabeled somatostatin analog indicated for:

– The treatment of gastroenteropancreatic tumors positive for the somatostatin receptor. Neuroendocrine tumors (GEP-NETs), including the foregut, midgut, and hindgut.

Línea

Nuclear Medicine

Sublínea

Radiation Therapy

177Lu DOTATATE (I+D)

Línea

Nuclear Medicine

Sublínea

Radiation Therapy

177Lu DOTATATE (I+D)

Nuclear Medicine

177Lu DOTATATE (I+D)

Name:
177Lu Dotatate (I+D)

Active Principle:
Lutetium (Lu 177)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl) acetyl]-Dphenylalanyl- L-cysteinyl-L-tyrosyl-D-tryptophanyl-L -lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic (2-7) disulfide.

Therapeutic Action:
It is a radiolabeled somatostatin analog indicated for:

– The treatment of gastroenteropancreatic tumors positive for the somatostatin receptor. Neuroendocrine tumors (GEP-NETs), including the foregut, midgut, and hindgut.

RELATED PRODUCTS